Can-Fite Secures Australian Patent for Namodenoson
Can-Fite BioPharma Ltd. announced that the Australian Patent Office has allowed Patent Application No. 2021290439, titled "Treatment of Advanced Metastatic Cancer." This patent allowance strengthens the company's global intellectual property portfolio for Namodenoson, supporting its development and marketing in liver and pancreatic cancer. Namodenoson is currently in a pivotal Phase 3 study for advanced hepatocellular carcinoma and has completed a Phase 2a study in pancreatic cancer, with a Phase 2b study planned.
Key Highlights
- Australian Patent Office allowed Patent Application No. 2021290439.
- Patent is entitled "Treatment of Advanced Metastatic Cancer."
- Supports Namodenoson development and marketing in liver and pancreatic cancer.
- Namodenoson is in pivotal Phase 3 for advanced hepatocellular carcinoma.
- Completed Phase 2a in pancreatic cancer, planning Phase 2b study.
- Strengthens global intellectual property portfolio for Namodenoson.
- Extends protection for therapeutic approach in a major international market.
Price Impact
More from CANF
Can-Fite BioPharma Secures Australian Patent for Advanced Metastatic Cancer Treatment
Can-Fite Completes Phase 3 Psoriasis Patient Enrollment for Interim Analysis
Can-Fite BioPharma Completes Enrollment for Phase 3 Psoriasis Study